Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Wong Mito Lab, |
RCV000714940 | SCV000845709 | likely pathogenic | Combined oxidative phosphorylation defect type 14 | 2018-06-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000714940 | SCV002150087 | uncertain significance | Combined oxidative phosphorylation defect type 14 | 2022-07-19 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 153 of the FARS2 protein (p.Arg153Gly). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of FARS2-related conditions (PMID: 28419689). ClinVar contains an entry for this variant (Variation ID: 587670). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FARS2 protein function. Experimental studies have shown that this missense change affects FARS2 function (PMID: 28419689). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |